Related Experiment Video
Updated: Jun 3, 2026
Induction and Analysis of Epithelial to Mesenchymal Transition
Published on: August 27, 2013
Pyrazolo-quinolinone suppresses epithelial-mesenchymal transition by targeting the CXCR4/NF-κB axis in human
Darshini Gowada1, Bada Yoon2, Young Yun Jung2
1Department of Studies in Chemistry, University of Mysore, Manasagangotri, Mysore, Karnataka 570006, India.
Abstract:
Pancreatic cancer (PC) is the most lethal type of malignancy with a minimal prognosis. It is often diagnosed at advanced disease stages, when existing therapeutics are largely ineffective. Epithelial-mesenchymal transition (EMT) is a biological phenomenon that enables epithelial cancer cells to acquire a mesenchymal phenotype and provides the cancer cells (including PC cells) with metastatic potential. Therefore, the discovery of small molecules with anti-EMT potential is important for conventional cytotoxic agents, as it may enable the inhibition of tumor progression and metastasis, alongside cytotoxicity. Herein, we investigated the anti-EMT potential of a synthetic pyrazolo-quinolinone derivative (designated RD-20) in PC cells. Biological activity was assessed through cell viability assays, migration/invasion assays, Western blotting, immunocytochemistry for EMT markers, and gelatin zymography. RD-20 exhibited marginal cytotoxicity in PC cells but significantly reduced mRNA and protein expression of chemokine receptors (CXCR4 and CXCR7) and protein levels of MMPs (MMP-2 and MMP-9), correlating with reduced invasive capacity. The expression of mesenchymal markers (Vimentin, Twist, and Snail) was reduced, while expression of epithelial markers (Occludin and E-cadherin) was increased upon RD-20 exposure, which was complemented by the results of immunocytochemistry. Functionally, RD-20 inhibited the invasion and migration of CXCL12-induced PC cells. A mechanistic approach revealed that RD-20 suppresses NF-κB activation, thereby blocking the expression of CXCR4, MMP-2, and MMP-9. Collectively, these findings indicate that RD-20 abrogates the NF-κB activation to induce anti-EMT effects in PC cells.
Insights
A novel compound, RD-20, shows potential in treating pancreatic cancer by inhibiting epithelial-mesenchymal transition (EMT). It reduces cancer cell invasion and metastasis by suppressing key molecular pathways, offering a new therapeutic avenue.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Pancreatic cancer (PC) is highly lethal, often diagnosed late with limited treatment options.
- Epithelial-mesenchymal transition (EMT) drives PC metastasis, making anti-EMT agents crucial.
- Targeting EMT could inhibit tumor progression and enhance cytotoxic therapies.
Purpose of the Study:
- To investigate the anti-EMT potential of a synthetic pyrazolo-quinolinone derivative, RD-20, in pancreatic cancer cells.
- To assess RD-20's effects on cell viability, migration, invasion, and EMT markers.
- To elucidate the molecular mechanisms underlying RD-20's anti-cancer activity.
Main Methods:
- Cell viability, migration, and invasion assays were performed.
- Western blotting and immunocytochemistry assessed EMT markers (Vimentin, Twist, Snail, Occludin, E-cadherin).
- Chemokine receptor (CXCR4, CXCR7) and MMP (MMP-2, MMP-9) expression was analyzed; NF-κB activation was investigated.
Main Results:
- RD-20 showed minimal cytotoxicity but significantly reduced PC cell invasion and migration.
- RD-20 decreased expression of mesenchymal markers and increased epithelial markers, indicating EMT inhibition.
- RD-20 suppressed NF-κB activation, leading to reduced CXCR4, MMP-2, and MMP-9 expression.
Conclusions:
- RD-20 effectively inhibits EMT in pancreatic cancer cells.
- The compound's anti-metastatic effects are mediated by suppressing NF-κB signaling.
- RD-20 represents a promising therapeutic candidate for pancreatic cancer treatment.
